Catalyst Wire Dossier Catalyst Wire Dossier

Aromasin (exemestane)

exemestane · Pfizer
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Aromasin (exemestane), covering 2024-12-09 to 2024-12-09. Get the full timeline:

Most recent: Clinical Trial Update: BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer [Phase 1]

See pricing